1. Epigenetics
  2. Epigenetic Reader Domain

Epigenetic Reader Domain

Epigenetic regulators of gene expression and chromatin state include so-called writers, erasers, and readers of chromatin modifications.Well-characterized examples of reader domains include bromodomains typically binding acetyllysine and chromatin organization modifier (chromo), malignant brain tumor (MBT), plant homeodomain (PHD), and Tudor domains generally associating with methyllysine. Research on epigenetic readers has been tremendously influenced by the discovery of selective inhibitors targeting the bromodomain and extraterminal motif (BET) family of acetyl-lysine readers. The human genome encodes 46 proteins containing 61 bromodomains clustered into eight families. Distinct experimental approaches are used to identify the first BET inhibitors, GSK 525762A and (+)-JQ-1.

The Polycomb group (PcG) protein, enhancer of zeste homologue 2 (EZH2), has an essential role in promoting histone H3 lysine 27 trimethylation (H3K27me3) and epigenetic gene silencing. This function of EZH2 is important for cell proliferation and inhibition of cell differentiation, and is implicated in cancer progression. Cyclin-dependent kinases regulate epigenetic gene silencing through phosphorylation of EZH2. In many types of cancers including lymphomas and leukemia, EZH2 is postulated to exert its oncogenic effects via aberrant histone and DNA methylation, causing silencing of tumor suppressor genes.

p300/CBP is not only a transcriptional adaptor but also a histone acetyltransferase.

Epigenetic Reader Domain Related Products (58):

Cat. No. Product Name Effect Purity
  • HY-13030
    (+)-JQ-1 Inhibitor 99.90%
    (+)-JQ-1 is a BET bromodomain inhibitor, with IC50 of 77 nM/33 nM for the first and second bromodomain (BRD4(1/2)).
  • HY-13803
    EPZ-6438 Inhibitor 99.63%
    EPZ-6438 inhibits the activity of human PRC2-containing wild-type EZH2 with Ki of 2.5±0.5 nM.
  • HY-13470
    GSK126 Inhibitor 99.32%
    GSK126 is a potent, highly selective inhibitor of EZH2 methyltransferase activity with IC50 of 9.9 nM.
  • HY-15743
    OTX-015 Inhibitor 99.69%
    OTX-015 is a new potent BRD2/3/4 inhibitor for cell adhesion with IC50 values from 92 to 112 nM.
  • HY-13032
    GSK 525762A Inhibitor 99.22%
    GSK 525762A is a BET bromodomain inhibitor with IC50 of 32.5-42.5 nM.
  • HY-101120
    666-15 Inhibitor 98.65%
    666-15 is a potent and selective CREB inhibitor with an IC50 of 81 nM.
  • HY-101146
    SF2523 Inhibitor 99.37%
    SF2523 is a highly selective and potent inhibitor of PI3K and BRD4 with IC50 values of 16 and 241 nM for PI3Kα and BD1, respectively.
  • HY-100653A
    AZD5153 6-Hydroxy-2-naphthoic acid Inhibitor 98.05%
    AZD5153 6-Hydroxy-2-naphthoic acid is the 6-Hydroxy-2-naphthoic acid of AZD5153.
  • HY-50698
    BI 2536 Inhibitor 99.19%
    BI 2536 is a potent and selective inhibitor of Plk1 with IC50 of 0.83 nM, and is also a potent inhibitor of BRD4 with IC50 of 25 nM.
  • HY-13500
    GSK343 Inhibitor 99.58%
    GSK343 is a highly potent, selective, and cell-active EZH2 inhibitor with IC50 of 4 nM.
  • HY-12186
    3-Deazaneplanocin A hydrochloride Inhibitor
    3-Deazaneplanocin A hydrochloride is a potent histone methyltransferase EZH2 inhibitor.
  • HY-15646
    UNC1999 Inhibitor 99.02%
    UNC1999 is a SAM-competitive, potent and selective inhibitor of EZH2 (IC50<10 nM) and EZH1 (IC50=45±3 nM).
  • HY-13235
    I-BET151 Inhibitor 98.47%
    I-BET151 is a BET bromodomain inhibitor, inhibits BRD4, BRD2, and BRD3 with pIC50 of 6.1, 6.3, and 6.6, respectively.
  • HY-11006
    KU-57788 Inhibitor 98.74%
    KU-57788 is a potent and selective inhibitor of DNA-PK, a modest inhibitor of BRD4 and BRDT, with IC50s of 13 nM, 1 μM and 3.5 μM, respectively, and also increases CRISPR/Cas9-mediated editing frequencies.
  • HY-16954
    ARV-825 Inhibitor 99.35%
    ARV-825 is a BRD4 Inhibitor based on PROTAC technology.
  • HY-15826
    SGC-CBP30 Inhibitor 99.19%
    SGC-CBP30 is a potent CREBBP/EP300 bromodomain inhibitor with IC50 of 21-69 and 38 nM for CREBBP and EP300 bromodomains, respectively)
  • HY-16652
    RVX-208 Inhibitor 99.19%
    RVX-208 is an inhibitor of BET transcriptional regulators with selectivity for the second bromodomain.
  • HY-78695
    JQ-1 carboxylic acid Inhibitor 99.49%
    (+)-JQ1 carboxylic acid is the carboxylic acid form of (+)-JQ1 for derivative synthesis.
  • HY-10409
    TG-101348 Inhibitor 98.28%
    TG-101348 is a selective inhibitor of JAK2 with IC50 of 3 nM, 35- and 334-fold more selective for JAK2 versus JAK1 and JAK3, and also inhibits BRD4 with IC50 of 340 nM.
  • HY-13030A
    (R)-(-)-JQ1 Enantiomer Inhibitor 99.61%
    (R)-(-)-JQ1 Enantiomer, the stereoisomer (+)-JQ1, showed no significant interaction with any bromodomain; (+)-JQ1 is an inhibitor for the BET.